Jack L. Wyszomierski Sells 8,768 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski sold 8,768 shares of the company’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of $37.80, for a total transaction of $331,430.40. Following the completion of the transaction, the director now directly owns 356,605 shares in the company, valued at approximately $13,479,669. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Exelixis Stock Up 2.8 %

Shares of NASDAQ EXEL opened at $38.69 on Friday. The firm has a market cap of $10.83 billion, a P/E ratio of 21.86, a PEG ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $38.72. The company has a 50 day moving average of $34.53 and a 200 day moving average of $31.62.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on EXEL shares. Truist Financial lifted their price objective on shares of Exelixis from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Stifel Nicolaus lifted their price target on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Wednesday, February 12th. Citigroup increased their price objective on Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Guggenheim restated a “buy” rating and issued a $42.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Finally, Morgan Stanley upgraded shares of Exelixis from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $30.00 to $40.00 in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and an average target price of $37.24.

Hedge Funds Weigh In On Exelixis

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. MassMutual Private Wealth & Trust FSB grew its stake in shares of Exelixis by 18.1% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 290 shares during the period. Balyasny Asset Management L.P. boosted its holdings in Exelixis by 1.9% in the fourth quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock worth $573,000 after purchasing an additional 317 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in Exelixis by 4.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 330 shares during the last quarter. Covestor Ltd grew its position in Exelixis by 5.7% in the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 341 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its stake in Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock valued at $1,937,000 after buying an additional 354 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.